WO2023203257A1 - Freeze dried compositions - Google Patents
Freeze dried compositions Download PDFInfo
- Publication number
- WO2023203257A1 WO2023203257A1 PCT/EP2023/060688 EP2023060688W WO2023203257A1 WO 2023203257 A1 WO2023203257 A1 WO 2023203257A1 EP 2023060688 W EP2023060688 W EP 2023060688W WO 2023203257 A1 WO2023203257 A1 WO 2023203257A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous composition
- pharmaceutically acceptable
- acceptable salt
- drug
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to a solid composition obtainable by freeze drying an aqueous composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug, as described herein.
- the present invention also relates to a reconstituted aqueous composition obtainable by reconstituting the solid composition of the invention, and a process for making the solid composition of the invention.
- a drug When a drug is to be administered by subcutaneous or intramuscular injection it may also be desirable to formulate it or to administer it with a hyaluronidase to increase dispersion and absorption of the drug.
- Hyaluronidase may also be used to achieve other effects - for example, the administration of a hyaluronidase may reduce the bump formed by the administration of high volumes of a pharmaceutical composition at injection sites.
- compositions comprising a drug for example compositions comprising rilpivirine
- hyaluronidases may unfold and degrade rapidly.
- the invention in a first aspect relates to a solid composition obtainable by freeze drying (synonymous with “lyophilising”) an aqueous composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug.
- a reconstituted aqueous composition obtainable by reconstituting the solid composition according to the first aspect.
- a method for the treatment or prevention of a disease or disorder in a subject comprising administering to the subject the reconstituted aqueous composition according to the second aspect.
- a reconstituted aqueous composition according to the second aspect for use in the treatment or prevention of a disease or disorder in a subject.
- a fifth aspect there is provided the use of the reconstituted aqueous composition according to the second aspect, for the manufacture of a medicament for treating or preventing a disease or disorder in a subject.
- a solid composition according to the first aspect for use in the treatment or prevention of a disease or disorder in a subject.
- a seventh aspect there is provided the use of the solid composition according to the first aspect for the manufacture of a medicament for treating or preventing a disease or disorder in a subject.
- cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof for stabilising a hyaluronidase in a solid composition comprising a drug.
- a method for stabilising a hyaluronidase in a solid composition comprising freeze drying an aqueous composition comprising the hyaluronidase, cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and a drug.
- kits comprising (i) the solid composition according to the first aspect, and (ii) a diluent.
- kits comprising: (i) the solid composition according to the first aspect, and (ii) a composition comprising one or more other drugs, and optionally (iii) a diluent.
- compositions of the invention are provided.
- the invention relates to a solid composition obtainable by freeze drying an aqueous composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug.
- the invention in a second aspect relates to a reconstituted aqueous composition obtainable by reconstituting the solid composition according to the first aspect.
- Freeze drying is a process in which an aqueous composition is initially frozen. During the initial freezing step, the water forms solid ice crystals and the composition concentrates leading to the separation of two phases. The pressure is then reduced during a primary drying stage, and the ice sublimes. The temperature may be increased in the primary drying stage to increase the rate of sublimation. In a secondary drying stage, the temperature of the composition is increased slowly to promote the removal of residual water and provide a solid composition.
- Solid compositions obtainable by freeze drying can be referred to by multiple terms, including “lyophilised powder”, “lyophilised cake”, “cake”, “freeze dried cake”, “freeze dried powder” and “freeze dried product”.
- the solid composition obtainable by freeze drying is a lyophilized cake, or cake or freeze- dried cake.
- a hyaluronidase is an enzyme that degrades hyaluronic acid (HA) e.g. in the skin and lowers the viscosity of hyaluronan in the extracellular matrix. Because of this property, it can be used to increase dispersion and absorption of injected active pharmaceutical ingredients and/or to enable administration of larger volumes subcutaneously.
- Enzymatic activity of hyaluronidase, including rHuPH20 can be defined by units per mL (U/mL) or by total enzyme activity in a particular formulation (U).
- hyaluronidase as used herein means any enzyme that degrades hyaluronic acid and lowers the viscosity of hyaluronan in the extracellular matrix.
- the hyaluronidase is recombinant hyaluronidase.
- the hyaluronidase is recombinant human hyaluronidase, e.g. rHuPH20.
- rHuPH20 is defined by the amino acid sequence available under CAS Registry No. 757971-58-7. Further information regarding rHuPH20 is provided in Int. Pat. Publ. No. W02004/078140.
- the amino acid sequence of rHuPH20 comprises SEQ ID NO: 1.
- the hyaluronidase is a variant of rHuPH20 having an amino acid sequence of rHuPH20 that comprises SEQ ID NO: 2, namely residues 36-482 of wild type human hyaluronidase.
- the hyaluronidase is a variant of rHuPH20 having an amino acid sequence that comprises SEQ ID NO: 3.
- the hyaluronidase is a variant of rHuPH20 having an amino acid sequence that comprises SEQ ID NO: 4.
- the hyaluronidase is a variant of rHuPH20 having an amino acid sequence that comprises SEQ ID NO: 5.
- the concentration of the hyaluronidase in the aqueous composition or the reconstituted aqueous composition is from about 10 to about 10,000 U/mL, or from about 100 to about 10,000 U/mL, or from about 500 to about 10,000 U/mL, or from about 500 to about 5,000 U/mL, or from about 500 to about 2500 U/mL, or from about 1000 to about 2500 U/mL, or from about 1500 to about 2500 U/mL.
- the concentration of the hyaluronidase in the aqueous composition or the reconstituted aqueous composition is from about 1800 to about 2200 U/mL (e.g. about 2000 U/mL).
- the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof is a carboxymethyl cellulose (CMC) or a pharmaceutically acceptable salt thereof, preferably wherein the CMC is not cross-linked.
- the CMC or a pharmaceutically acceptable salt of CMC is a pharmaceutically acceptable salt of CMC.
- Pharmaceutically acceptable salts of CMC means those where the counterion is pharmaceutically acceptable.
- the pharmaceutically acceptable salts are meant to comprise the therapeutically active non-toxic base addition salt forms which CMC is able to form.
- Preferred pharmaceutically acceptable salts of CMC include sodium CMC and potassium CMC.
- the CMC or a pharmaceutically acceptable salt thereof is sodium CMC, particularly non-cross-linked sodium CMC.
- the CMC or a pharmaceutically acceptable salt thereof is CMC.
- CMCs that may be used in the invention are carmellose sodium, 40 mPa.s (parenteral grade), available from Ashland, and Blanose CMC 7LF PH or Blanose 7LP EP, available from Ashland.
- the CMC or a derivative thereof or a pharmaceutically acceptable salt thereof can have any degree of substitution (DS).
- the DS is the average number of carboxymethyl groups per cellulose unit. In a preferred embodiment, the DS is from about 0.4 to about 1 .5. In an embodiment, the CMC or a pharmaceutically acceptable salt thereof has a DS of from about 0.5 to about 1 , for example from about 0.65 to about 0.95 such as about 0.7.
- the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 10 mPa.s to about 100 mPa.s in an aqueous solution of 1% (w/v) at room temperature. In an embodiment, the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 20 mPas to about 60 mPa.s in an aqueous solution of 1% (w/v) at room temperature.
- the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 30 mPa.s to about 50 mPa.s in an aqueous solution of 1% (w/v) at room temperature, for example about 40 mPa.s in an aqueous solution of 1% (w/v) at room temperature.
- the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 10 mPa.s to about 100 mPa.s in an aqueous solution of 2% (w/v) at room temperature. In an embodiment, the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 20 mPas to about 60 mPa.s in an aqueous solution of 2% (w/v) at room temperature.
- the CMC or a pharmaceutically acceptable salt thereof has a viscosity of from about 30 mPa.s to about 50 mPa.s in an aqueous solution of 2% (w/v) at room temperature, for example about 40 mPa.s in an aqueous solution of 2% (w/v) at room temperature.
- the molecular weight of the CMC or a pharmaceutically acceptable salt thereof is from about 50 kDa to about 2,000 kDa. In an embodiment, the molecular weight of the CMC or a pharmaceutically acceptable salt thereof is from about 50 kDa to about 1 ,000 kDa. In an embodiment, the molecular weight of the CMC or a pharmaceutically acceptable salt thereof is from about 70 kDa to about 900 kDa. In a preferred embodiment, the molecular weight of the CMC or a pharmaceutically acceptable salt thereof is from about 90 kDa to about 750 kDa.
- the molecular weight of the CMC or a pharmaceutically acceptable salt thereof is from about 70 kDa to about 110 kDa, for example about 90 kDa.
- T m melting temperature of a hyaluronidase
- a cellulose e.g. CMC
- a derivative thereof e.g. CMC
- a pharmaceutically acceptable salt thereof e.g. a cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, to the aqueous compositions of the invention which comprise a hyaluronidase leads to a decrease in the loss of hyaluronidase activity, decrease in aggregation of the hyaluronidase, and/or decrease in oxidation of the hyaluronidase in the reconstituted aqueous composition of the invention, such as following storage of the freeze dried product under stress test conditions (Examples 5 and 7). This is indicative of improved stability on storage.
- a cellulose e.g. CMC
- the aqueous composition or the reconstituted aqueous composition comprises from about 0.1 mg/mL to about 100 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 100 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 75 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 50 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 25 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 5 mg/mL to about 25 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the aqueous composition or the reconstituted aqueous composition comprises from about 5 mg/mL to about 15 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In a preferred embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 5 mg/mL to about 10 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof. In a most preferred embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 5 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, e.g. about 3 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof is sodium CMC and the aqueous composition or the reconstituted aqueous composition comprises the sodium CMC in any one of the amounts specified in the paragraph directly above.
- the CMC or a pharmaceutically acceptable salt thereof is sodium CMC and the aqueous composition or the reconstituted aqueous composition has any of the degrees of substitution, viscosities and molecular weights specified herein.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.002 mg to about 5 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.01 mg to about 5 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.05 mg to about 2.5 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.1 mg to about 2 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.1 mg to about 1 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.1 mg to about 0.25 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase, e.g. about 0.15 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.05 mg to about 0.25 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase, e.g. about 0.15 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof is sodium CMC and the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises any one of the ratios of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to hyaluronidase, specified in the paragraph directly above.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises a cryoprotectant.
- the cryoprotectant is a sugar, sugar alcohol, or amino acid or a pharmaceutically acceptable salt thereof, preferably wherein the sugar is not a monosaccharide.
- Pharmaceutically acceptable salts of the cryoprotectant means those where the counterion is pharmaceutically acceptable.
- the pharmaceutically acceptable salts are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which a given sugar, sugar alcohol or an amino acid is able to form.
- the cryoprotectant is a sugar or sugar alcohol, preferably wherein the sugar is not a monosaccharide.
- Suitable sugars and sugar alcohols include mannitol, lactose, sucrose, trehalose, sorbitol, dextrose, fructose, maltose, xylitol and raffinose.
- the sugar or sugar alcohol is selected from mannitol and sucrose. More preferably, the sugar or sugar alcohol is sucrose.
- Suitable amino acids or pharmaceutically acceptable salts thereof include arginine, glycine and histidine or a pharmaceutically acceptable salt thereof. In an embodiment, the amino acid or a pharmaceutically acceptable salt thereof is selected from arginine and glycine or a pharmaceutically acceptable salt thereof.
- the amino acid or a pharmaceutically acceptable salt thereof is arginine (e.g. arginine HCI).
- the aqueous composition (and, therefore, the solid composition) or the reconstituted aqueous composition additionally comprises two cryoprotectants.
- the aqueous composition (and, therefore, the solid composition) or the reconstituted aqueous composition additionally comprises two cryoprotectants, wherein one cryoprotectant is a sugar or sugar alcohol and the other cryoprotectant is an amino acid or a pharmaceutically acceptable salt thereof.
- the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 200 mg/mL of the cryoprotectant. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 175 mg/mL of the cryoprotectant. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 mg/mL to about 150 mg/mL of the cryoprotectant. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 20 mg/mL to about 150 mg/mL of the cryoprotectant.
- the aqueous composition or the reconstituted aqueous composition comprises a cryoprotectant which is a sugar or sugar alcohol in an amount of from about 25 mg/mL to about 150 mg/mL. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises a cryoprotectant which is a sugar or sugar alcohol in an amount of from about 25 mg/mL to about 125 mg/mL cryoprotectant. In a preferred embodiment, the aqueous composition or the reconstituted aqueous composition comprises a cryoprotectant which is a sugar or sugar alcohol in an amount of from about 50 mg/mL to about 100 mg/mL cryoprotectant.
- the aqueous composition or the reconstituted aqueous composition comprises a cryoprotectant which is a sugar or sugar alcohol in an amount of from about 75 mg/mL to about 125 mg/mL, e.g. about 100 mg/mL.
- the cryoprotectant is sucrose.
- the aqueous composition or the reconstituted aqueous composition comprises a cryoprotectant which is an amino acid or a pharmaceutically acceptable salt thereof in an amount of from about 1 mg/mL to about 100 mg/mL.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a cryoprotectant which is an amino acid or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/mL to about 50 mg/mL.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a cryoprotectant which is an amino acid or a pharmaceutically acceptable salt thereof in an amount of from about 25 mg/mL to about 35 mg/mL, e.g. about 30 mg/mL.
- the cryoprotectant is arginine, preferably arginine HCI.
- the aqueous composition or the reconstituted aqueous composition comprises two cryoprotectants, wherein the total amount of the two cryoprotectants is from about 25 mg/mL to about 150 mg/mL, preferably wherein the two cryoprotectants are a sugar or sugar alcohol and an amnio acid.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises sucrose and cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises sucrose and sodium CMC.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises arginine or a pharmaceutically acceptable salt thereof and cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises arginine hydrochloride and sodium CMC.
- the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 1 :100 (w/w). In an embodiment, the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 1 :50 (w/w).
- the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 1 :40 (w/w). In a preferred embodiment, the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :8 (w/w) to about 1 :40 (w/w).
- the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :8 (w/w) to about 1 :35 (w/w), e.g. about 1 :10 (w/w) to about 1 :33 (w/w).
- the cryoprotectant is arginine or a pharmaceutically acceptable salt thereof, e.g. arginine HCI, and the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 1 :15 (w/w).
- the cryoprotectant is arginine or a pharmaceutically acceptable salt thereof, e.g.
- cryoprotectant is arginine or a pharmaceutically acceptable salt thereof, e.g.
- cryoprotectant is arginine or a pharmaceutically acceptable salt thereof, e.g.
- cryoprotectant is arginine or a pharmaceutically acceptable salt thereof, e.g.
- arginine HCI and the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :5 (w/w) to about 1 :10 (w/w).
- the cryoprotectant is sucrose, and the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :30 (w/w) to about 1 :50 (w/w).
- the cryoprotectant is sucrose, and the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :30 (w/w) to about 1 :40 (w/w).
- the cryoprotectant is sucrose, and the ratio of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :30 (w/w) to about 1 :35 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises water, e.g. sterile water for injection.
- the pH of the aqueous composition or the reconstituted aqueous composition is from about 5 to about 7. In an embodiment, the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 7. In an embodiment, the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5. In a preferred embodiment, the pH of the aqueous composition or the reconstituted aqueous composition is about 6.
- the pH of the aqueous composition or the reconstituted aqueous composition may be adjusted by, for example, varying the type and/or amount of buffering agent and/or pH adjusting agent present in the aqueous composition.
- drug includes any substance that is biologically active.
- the substance may be free base, free acid or pharmaceutically acceptable salt thereof, and also encompasses tautomers, solvates (e.g. hydrates) and crystalline or amorphous solid forms thereof, and the like.
- drug also includes prodrugs.
- the drug is not a biologic.
- biological it is meant a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition, for example, of human beings.
- the drug is not an antibody.
- the drug has a molecular weight (MW) of less than 1000 Da.
- the drug has a molecular weight (MW) of less than 1000 Da and is not a biologic.
- the drug is selected from drugs for treatment of chronic and long-term diseases and disorders, for example for treatment of chronic viral infection (such as chronic infection with Varicella-zoster virus, measles virus, human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, hepatitis D virus or human cytomegalovirus), cancer, psychiatric diseases and disorders, mood disorders (such as bipolar, cyclothymic or depression), diabetes, hypertension, abnormal cholesterol and triglyceride levels, inflammatory disorders (such as allergy, asthma, autoimmune diseases, coeliac disease, hepatitis, inflammatory bowel disease, Crohn disease, gout, myositis, scleroderma, rheumatoid arthritis, lupus vasculitis, ankylosing spondylitis or chronic obstructive pulmonary disease), cystic fibrosis, multiple sclerosis, autoimmune disorders, neurodegenerative disorders (such as Parkinson Disease or
- the drug is rilpivirine (TMC278), or a pharmaceutically acceptable salt thereof, preferably rilpivirine.
- Rilpivirine (4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile; TMC278) has the following structural formula:
- rilpivirine it is meant rilpivirine having the structural formula shown above, i.e. the free base form.
- compositions of rilpivirine means those where the counterion is pharmaceutically acceptable.
- the pharmaceutically acceptable salts are meant to comprise the therapeutically active non-toxic acid addition salt forms which rilpivirine is able to form. These salt forms can conveniently be obtained by treating rilpivirine with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
- hydrochloric, hydrobromic and the like sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1 ,2,3-propanetri carboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzene sulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
- organic acids for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1 ,2,3-propane
- the aqueous composition comprises the drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition.
- the aqueous composition or the reconstituted aqueous composition comprises the drug in the form of micro- or nanoparticles suspended in the aqueous composition or the reconstituted aqueous composition.
- the particles have a D v 90 of less than or about 2 pm.
- the particles may have a D v 90 of from about 100 nm to about 2 pm.
- the particles may have a D v 90 of from about 200 nm to about 2 pm, for example, of from 200 nm to about 2 pm.
- the particles may have a D v 90 of from about 300 nm to about 2 pm, for example, of from 300 nm to about 2 pm.
- the particles may have a D v 90 of from about 400 nm to about 2 pm, for example, of from 400 nm to about 2 pm.
- the particles may have a D v 90 of from about 500 nm to about 2 pm, for example, of from 500 nm to about 2 pm.
- the particles have a D v 90 of from about 500 nm to about 1 ,600 nm, for example, of from 500 nm to about 1 ,600 nm or a D v 90 of from about 500 nm to about 1 ,000 nm, for example, of from 500 nm to about 1 ,000 nm, for example about 800 nm.
- the particles have a D v 90 of about 500 nm to about 700 nm, for example about 500 nm to about 650 nm, and most preferably from about 525 nm to about 644 nm.
- D v 90 refers to the diameter below which 90% by volume of the particle population is found.
- D v 50 refers to the diameter below which 50% by volume of the particle population is found.
- D v 10 refers to the diameter below which 10% by volume of the particle population is found.
- the particles may have a D v 50 of less than or about 1 ,000 nm. In this embodiment, the particles may have a D v 50 of from about 10 nm to about 1 ,000 nm. In this embodiment, the particles may have a D v 50 of from about 50 nm to about 700 nm. In this embodiment, the particles may have a D v 50 of from about 100 nm to about 600 nm. In this embodiment, the particles may have a D v 50 of from about 150 nm to about 500 nm. Preferably in this embodiment, the particles have a D v 50 of from about 200 nm to about 500 nm.
- the particles may have a D v 10 of less than or about 500 nm.
- the particles may have a D v 10 of from about 10 nm to about 500 nm.
- the particles may have a D V 10 of from about 25 nm to about 400 nm.
- the particles may have a D v 10 of from about 50 nm to about 300 nm.
- the particles may have a D v 10 of from about 50 nm to about 200 nm.
- the particles Preferably in this embodiment, the particles have a D v 10 of from about 75 nm to about 200 nm.
- the particles have a D v 90 of from about 500 nm to about 1 ,600 nm, a D v 50 of from about 200 nm to about 500 nm and a D V 10 of from about 75 nm to about 200 nm.
- the particles have a D v 90 of from about 500 nm to about 1 ,000 nm, a D v 50 of from about 200 nm to about 500 nm and a D v 10 of from about 75 nm to about 200 nm.
- the particles have a D v 90 of from about 500 nm to about 700 nm, a D v 50 of from about 200 nm to about 500 nm and a D v 10 of from about 75 nm to about 200 nm.
- the particles may have a D v 90 of from about 1 pm to about 10 pm. In this embodiment, the particles may have a D v 90 of from about 2 pm to about 9 pm. In this embodiment, the particles may have a D v 90 of from about 3 pm to about 8 pm. In this embodiment, the particles may have a D v 90 of from about 3 pm to about 7 pm. Preferably in this embodiment, the particles have a D v 90 of from about 4 pm to about 6 pm. Most preferably in this embodiment, the particles have a D v 90 of about 5 pm to about 6 pm, e.g. about 5 pm or about 6 pm.
- the particles have a D v 50 of less than or about 3 pm. In this embodiment, the particles may have a D v 50 of less than 2.5 pm. In this embodiment, the particles may have a D v 50 of from about 1 pm to about 2.5 pm. In this embodiment, the particles may have a D v 50 of from about 1 .2 pm to about 2.2 pm.
- the particles have a D v 50 of from about 1.5 pm to about 2.2 pm. Further preferably in this embodiment, the particles have a D v 50 of from about 1.5 pm to about 2 pm.
- the particles may have a D v 10 of less than or about 1000 nm. In this embodiment, the particles may have a D v 10 of from about 10 nm to about 1000 nm. In this embodiment, the particles may have a D v 10 of from about 100 nm to about 700 nm. In this embodiment, the particles may have a D v 10 of from about 200 nm to about 600 nm. Preferably in this embodiment, the particles have a D v 10 of from about 300 nm to about 500 nm.
- the particles have a D v 90 of from about 4 pm to about 6 pm, a D v 50 of from about 1.5 pm to about 2 pm and a D v 10 of from about 300 nm to about 500 nm.
- the particles have a D v 90 of from about 5 pm to about 6 pm, a D v 50 of from about 1.5 pm to about 2.2 pm and a D v 10 of from about 300 nm to about 500 nm.
- compositions of the invention particle size distribution of the drug particles was similarto that in the aqueous composition prior to the freeze drying.
- the D v 10, D v 50 and D v 90 as used herein are determined by routine laser diffraction techniques, e.g. in accordance with ISO 13320:2009.
- Laser diffraction relies on the principle that a particle will scatter light at an angle that varies depending on the size the particle and a collection of particles will produce a pattern of scattered light defined by intensity and angle that can be correlated to a particle size distribution.
- a number of laser diffraction instruments are commercially available for the rapid and reliable determination of particle size distributions.
- particle size distribution may be measured by the conventional Malvern MastersizerTM 3000 particle size analyser from Malvern Instruments.
- the Malvern MastersizerTM 3000 particle size analyser operates by projecting a helium-neon gas laser beam through a transparent cell containing the particles of interest suspended in an aqueous solution.
- Light rays which strike the particles are scattered through angles which are inversely proportional to the particle size and a photodetector array measures the intensity of light at several predetermined angles and the measured intensities at different angles are processed by a computer using standard theoretical principles to determine the particle size distribution.
- Laser diffraction values may be obtained using a wet dispersion of the particles in distilled water.
- D v 10, D v 50 and D v 90 include disc centrifugation, scanning electron microscope (SEM), sedimentation field flow fractionation and photon correlation spectroscopy.
- the aqueous composition or the reconstituted aqueous composition comprises from about 0.01 to about 500 mg/mL of the drug. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 1 to about 500 mg/mL of the drug. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 10 to about 500 mg/mL of the drug. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 100 to about 500 mg/mL of the drug. In an embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 150 to about 450 mg/mL of the drug.
- the aqueous composition or the reconstituted aqueous composition comprises from about 200 to about 400 mg/mL of the drug. In a preferred embodiment, the aqueous composition or the reconstituted aqueous composition comprises from about 250 to about 350 mg/mL of the drug, e.g. about 300 mg/mL.
- the amount of the drug in the aqueous composition (and, therefore, the solid composition) or reconstituted aqueous composition is from about 0.03 mg to about 28800 mg, or from about 3 mg to about 28800 mg, or from about 30 mg to about 28800 mg, or from about 300 mg to about 28800 mg, or from about 900 mg to about 28800 mg (e.g. from about 900 mg to about 14400 mg, or from about 900 mg to about 7200 mg, or from about 900 mg to about 4500 mg, or from about 900 mg to about 3600 mg), preferably from about 1200 mg to about 14400 mg, preferably from about 1350 mg to about 13200 mg, preferably from about 1500 mg to about 12000 mg, (e.g.
- rilpivirine i.e. rilpivirine in its free base form
- rilpivirine hydrochloride corresponds to 1.1 mg of rilpivirine hydrochloride.
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 20:1 (w/w). In an embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 10:1 (w/w). In an embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 2:1 (w/w) to about 10:1 (w/w).
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 2:1 (w/w) to about 7:1 (w/w). In a preferred embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 3:1 (w/w) to about 6:1 (w/w).
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 15:1 (w/w). In a particularly preferred embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 5:1 (w/w), for example about 3:1 (w/w).
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 8:1 (w/w) to about 12:1 (w/w), for example about 10:1 (w/w).
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :1 (w/w) to about 1 :10 (w/w). In an embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :2 (w/w) to about 1 :10 (w/w).
- the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :2 (w/w) to about 1 :7 (w/w). In a preferred embodiment, the ratio of drug to cryoprotectant in the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition is from about 1 :3 (w/w) to about 1 :6 (w/w). In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises one or more surface modifiers. When the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises a drug in the form of particles as defined herein, the one or more surface modifiers is adsorbed to the surface of the particles.
- the surface modifier may be selected from known organic and inorganic pharmaceutical excipients, including various polymers, low molecular weight oligomers, natural products and surfactants. Particular surface modifiers that may be used in the invention include nonionic and anionic surfactants. Representative examples of surface modifiers include gelatin, casein, lecithin, salts of negatively charged phospholipids or the acid form thereof (such as phosphatidyl glycerol, phosphatidyl inosite, phosphatidyl serine, phosphatic acid, and their salts such as alkali metal salts, e.g.
- egg phosphatidyl glycerol sodium such as the product available under the tradename LipoidTM EPG
- gum acacia stearic acid
- benzalkonium chloride polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives; polyoxyethylene stearates, colloidal silicon dioxide, sodium dodecylsulfate bile salts such as sodium taurocholate, sodium desoxytaurocholate, sodium desoxycholate; methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, magnesium aluminate silicate, polyvinyl alcohol (PVA), poloxamers, such as PluronicTM F68, F 108 and F 127 which are block copolymers of ethylene oxide and propylene oxide; tyloxapol; Vitamin E-TGPS (a -tocopheryl polyethylene
- the surface modifier is selected from a poloxamer, a-tocopheryl polyethylene glycol succinate, polyoxyethylene sorbitan fatty acid ester, and salts of negatively charged phospholipids or the acid form thereof.
- the surface modifier is selected from PluronicTM F108, Vitamin E TGPS(a-tocopheryl polyethylene glycol succinate, in particular a-tocopheryl polyethylene glycol 1000 succinate), polyoxyethylene sorbitan fatty acid esters such as TweenTM 80, and phosphatidyl glycerol, phosphatidyl inosite, phosphatidyl serine, phosphatic acid, and their salts such as alkali metal salts, e.g. their sodium salts, for example egg phosphatidyl glycerol sodium, such as the product available under the tradename LipoidTM EPG.
- PluronicTM F108 Vitamin E TGPS(a-tocopheryl polyethylene glycol succinate, in particular a-tocopheryl polyethylene glycol 1000 succinate)
- polyoxyethylene sorbitan fatty acid esters such as TweenTM 80
- phosphatidyl glycerol phosphatidyl inosite
- the surface modifier is a poloxamer, in particular PluronicTM F108.
- PluronicTM F108 corresponds to poloxamer 338 and is the polyoxyethylene, polyoxypropylene block copolymer that conforms generally to the formula HO-[CH 2 CH 2 O] X - [CH(CH3)CH 2 O]y-[CH2CH 2 O]z-H in which the average values of x, y and z are respectively 128, 54 and 128.
- Other commercial names of poloxamer 338 are Hodag NonionicTM 1108-F and SynperonicTM PE/F108.
- the surface modifier comprises a combination of a polyoxyethylene sorbitan fatty acid ester and a phosphatidyl glycerol salt (in particular egg phosphatidyl glycerol sodium).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 0.1 mg/mL to about 100 mg/mL of a poloxamer. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 100 mg/mL of a poloxamer. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 70 mg/mL of a poloxamer. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 60 mg/mL of a poloxamer.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 25 mg/mL of a poloxamer. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 20 mg/mL of a poloxamer, e.g. about 20 mg/mL. In a preferred embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 5 mg/mL to about 15 mg/mL of a poloxamer, e.g. about 10 mg/mL.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 20 mg/mL to about 60 mg/mL of a poloxamer. In an embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 25 mg/mL to about 60 mg/mL of a poloxamer. In a particularly preferred embodiment, the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 40 mg/mL to about 60 mg/mL of a poloxamer, e.g. about 50 mg/mL.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a poloxamer and a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, wherein when drug has a Dv90 of less than about 1600 nm the ratio of the drug to poloxamer is less than about 15:1 (w/w).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a poloxamer and a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer is from about 15:1 (w/w) to about 3:1 (w/w).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a poloxamer and a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, wherein when the drug has a Dv90 of less than about 1600 nm the ratio of the drug to poloxamer is from about 15:1 (w/w) to about 4:1 (w/w).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a poloxamer and a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer is from about 15:1 (w/w) to about 6:1 (w/w).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a poloxamer and a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer is about 6:1 (w/w).
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition and a poloxamer, the ratio of the drug to poloxamer is more than about 15:1 (w/w), and the drug has a Dv90 of from about 1 pm to about 10 pm, from about 2 pm to about 9 pm, from about 3 pm to about 8 pm, or from about 3 pm to about 7 pm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is from about 15:1 (w/w) to about 60: (w/w)1 , and the drug has a Dv90 of from about 1 pm to about 10 pm, from about 2 pm to about 9 pm, from about 3 pm to about 8 pm, or from about 3 pm to about 7 pm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is from about 20:1 (w/w) to about 60:1 (w/w), and the drug has a Dv90 of from about 1 pm to about 10 pm, from about 2 pm to about 9 pm, from about 3 pm to about 8 pm, or from about 3 pm to about 7 pm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is from about 30:1 (w/w) to about 60:1 (w/w), and the drug has a Dv90 of from about 1 pm to about 10 pm, from about 2 pm to about 9 pm, from about 3 pm to about 8 pm, or from about 3 pm to about 7 pm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is about 30:1 (w/w), and the drug has a Dv90 of from about 1 pm to about 10 pm, from about 2 pm to about 9 pm, from about 3 pm to about 8 pm, or from about 3 pm to about 7 pm, e.g. from about 4 pm to about 6 pm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is less than about 15:1 (w/w), and the drug has a Dv90 of from about 500 nm to about 1600 nm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is from about 3:1 (w/w) to about 15:1 (w/w), and the drug has a Dv90 of from about 500 nm to about 1600 nm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is 4:1 (w/w) to about 15:1 (w/w), and the drug has a Dv90 of from about 500 nm to about 1600 nm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is 6:1 (w/w) to about 15:1 (w/w), and the drug has a Dv90 of from about 500 nm to about 1600 nm.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition, and a poloxamer, the ratio of the drug to poloxamer is about 6:1 (w/w), and the drug has a Dv90 of from about 500 nm to about 1600 nm, e.g. about 500 nm to about 700 nm.
- the relative amount (w/w) of drug to the surface modifier is from about 1 :1 (w/w) to about 40:1 (w/w). In an embodiment, the relative amount (w/w) of drug to the surface modifier is from about 1 :1 (w/w) to about 35:1 (w/w). In an embodiment, the relative amount (w/w) of drug to the surface modifier is from about 15:1 (w/w) to about 35:1 (w/w). In an embodiment, the relative amount (w/w) of drug to the surface modifier is from about 25:1 (w/w) to about 35:1 (w/w), e.g. about 30:1 (w/w).
- the surface modifier is preferably a poloxamer.
- the relative amount (w/w) of drug to the surface modifier is from about 5:1 to about 25:1 . In an embodiment, the relative amount (w/w) of drug to the surface modifier is from about 10:1 to about 20:1 . In an embodiment, the relative amount (w/w) of drug to the surface modifier is from about 13:1 to about 17:1 , e.g. about 15:1 .
- the surface modifier is preferably a poloxamer. In an embodiment, the relative amount (w/w) of drug to the surface modifier (e.g. a poloxamer) is less than about 15:1. In a preferred embodiment, the relative amount (w/w) of drug to the surface modifier (e.g. a poloxamer) is less than about 12:1.
- the relative amount (w/w) of drug to the surface modifier is from about 1 :2 to about 20: 1 , in particular from about 1 : 1 to about 10:1 , such as from about 4: 1 to about 8:1 , e.g. from about 4:1 to about 6:1 , preferably about 6:1.
- the surface modifier is preferably a poloxamer.
- the aqueous composition or the reconstituted aqueous composition comprises a drug as defined herein in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition and one or more surface modifiers as defined herein wherein the amount of the drug is at least about 50% by weight of the particles, at least about 80% by weight of the particles, at least about 85% by weight of the particles, at least about 90% by weight of the particles, at least about 95% by weight of the particles, or at least about 99% by weight of the particles, in particular ranges between 80% and 90% by weight of the particles or ranges between 85% and 90% by weight of the particles.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises a buffering agent and/or a pH adjusting agent.
- buffers are the salts of weak acids.
- Buffering and pH adjusting agents that can be added may be selected from tartaric acid, maleic acid, glycine, sodium lactate/lactic acid, ascorbic acid, sodium citrates/citric acid, sodium acetate/acetic acid, sodium bicarbonate/carbonic acid, sodium succinate/succinic acid, sodium benzoate/benzoic acid, sodium phosphates, tris(hydroxymethyl)aminomethane, sodium bicarbonate/sodium carbonate, ammonium hydroxide, benzene sulfonic acid, benzoate sodium/acid, diethanolamine, glucono delta lactone, hydrochloric acid, hydrogen bromide, lysine, methanesulfonic acid, monoethanolamine, sodium hydroxide, trometh
- the buffer is a sodium phosphate buffer, e.g. sodium dihydrogen phosphate monohydrate.
- the pH adjusting agent is sodium hydroxide.
- the aqueous composition or the reconstituted aqueous composition comprises a buffering agent and a pH adjusting agent, wherein the buffering agent is sodium dihydrogen phosphate monohydrate and the pH adjusting agent is sodium hydroxide.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises a chelating agent.
- the chelating agent is selected form sodium citrate, sodium EDTA, citric acid and malic acid.
- the chelating agent is citric acid, e.g. citric acid monohydrate.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition additionally comprises an antioxidant.
- the antioxidant is methionine.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition comprises from about 1 .0 mg/mL to about 2.0 mg/mL of the antioxidant (e.g. methionine), for example about 1.5 mg/mL.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition does not comprise an isotonizing agent.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition does not comprise glucose.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition does not comprise mannitol.
- the aqueous composition (and, as a consequence, the solid composition) or the reconstituted aqueous composition does not comprise a polyvinyl pyrrolidone (PVP).
- PVP polyvinyl pyrrolidone
- the aqueous composition and the reconstituted aqueous composition may usefully have osmolality suitable to reduce pain on subcutaneous injection.
- the aqueous composition and reconstituted aqueous composition has an osmolality of from about 280 mOsm/kg to about 600 mOsm/kg.
- the aqueous composition and reconstituted aqueous composition has an osmolality of from about 280 mOsm/kg to about 300 mOsm/kg.
- the aqueous composition and reconstituted aqueous composition has an osmolality of about 290 mOsm/kg.
- the aqueous composition or the reconstituted aqueous composition of the invention may be housed in a container with an inert gas.
- the inert gas may, for example, be nitrogen.
- the aqueous composition or the reconstituted aqueous composition comprises: a hyaluronidase; a drug; and
- the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 7, optionally from about 6 to about 6.5.
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; and sodium CMC, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5.
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; and sodium CMC, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5, and wherein the aqueous composition comprises from about 0.5 mg sodium CMC per 100 U rHuPH20 to about 2 mg sodium CMC per 100 U rHuPH20,
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; and sodium CMC, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5, and wherein the aqueous composition comprises from about 0.05 mg sodium CMC per 100 U rHuPH20 to about 0.25 mg sodium CMC per 100 U rHuPH20,
- the aqueous composition or the reconstituted aqueous composition comprises: a hyaluronidase; a drug;
- the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 7, optionally from about 6 to about 6.5.
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug;
- the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5.
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; sodium CMC; and mannitol and/or sucrose, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5, wherein the aqueous composition or the reconstituted aqueous composition comprises from about 0.5 mg sodium CMC per 100 U rHuPH20 to about 2 mg sodium CMC per 100 U rHuPH20, and wherein the ratio of sodium CMC to mannitol or sucrose is from about 1 :4 (w/w) to about 1 :11 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; sodium CMC; and sucrose, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5, wherein the aqueous composition or the reconstituted aqueous composition comprises from about 0.05 mg sodium CMC per 100 U rHuPH20 to about 0.25 mg sodium CMC per 100 U rHuPH20, and wherein the ratio of sodium CMC to sucrose is from about 1 :30 (w/w) to about 1 :35 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug;
- the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5.
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; sodium CMC; and arginine HCI, wherein the pH of the aqueous composition or the reconstituted aqueous composition is from about 6 to about 6.5, wherein the aqueous composition or the reconstituted aqueous composition comprises from about 0.05 mg sodium CMC per 100 U rHuPH20 to about 0.25 mg sodium CMC per 100 U rHuPH20, and wherein the ratio of sodium CMC to arginine HCI is from about 1 :9 (w/w) to about 1 :11 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; sodium CMC; sucrose; and poloxamer 338, optionally wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer 338 is from about 3:1 (w/w) to about 15:1 (w/w), e.g. about 6:1 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: from about 1800 to about 2200 U/mL rHuPH20; from about 250 to about 350 mg/mL of a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition; from about 1 mg/mL to about 5 mg/mL sodium CMC; from about 75 mg/mL to about 125 mg/mL sucrose; and from about 5 mg/mL to about 60 mg/mL poloxamer 338, optionally wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer 338 is from about 3:1 (w/w) to about 15:1 (w/w), e.g. about 6:1 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: rHuPH20; a drug; sodium CMC; arginine HCI; and poloxamer 338, optionally wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer 338 is from about 3:1 (w/w) to about 15:1 (w/w), e.g. about 6:1 (w/w).
- the aqueous composition or the reconstituted aqueous composition comprises: from about 1800 to about 2200 U/mL rHuPH20; from about 250 to about 350 mg/ml_ of a drug in the form of particles suspended in the aqueous composition or the reconstituted aqueous composition; from about 1 mg/mL to about 5 mg/mL sodium CMC; from about 25 mg/mL to about 35 mg/mL arginine HCI; and from about 5 mg/mL to about 60 mg/mL poloxamer 338, optionally wherein when the drug has a Dv90 of less than about 1600 nm the ratio of drug to poloxamer 338 is from about 3:1 (w/w) to about 15:1 (w/w), e.g. about 6:1 (w/w).
- the invention also relates to the freeze dried compositions corresponding to the particular embodiments above.
- the aqueous composition or the reconstituted aqueous composition may additionally further comprise an antioxidant (e.g. methionine), optionally in an amount of from about 1 .0 mg/mL to about 2.0 mg/mL (e.g. 1 .5 mg/mL).
- an antioxidant e.g. methionine
- the particles may have a Dv90 of from about 1 pm to about 10 pm (e.g. about 5 pm to about 6 pm). Alternatively, unless specified otherwise, in any of the particular embodiments above the particles may have a Dv90 of from about 500 nm to about 1600 nm (e.g. about 500 nm to about 700 nm).
- the invention also relates to a solid composition
- a solid composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug.
- the solid composition may optionally have features (e.g. excipients, amounts and pH) and combinations of features as described herein in relation to the aqueous composition and solid composition of the first aspect of the invention.
- the invention also relates to a solid composition
- a solid composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, (iii) a drug, and (iv) a cryoprotectant as defined in relation to the first aspect of the invention.
- the solid composition of the invention may be reconstituted to provide a reconstituted aqueous composition.
- the second aspect of the invention relates to a reconstituted aqueous composition obtainable by reconstituting the solid composition as defined herein.
- the reconstituted aqueous composition comprises the same components in the same amounts as the aqueous composition in the first aspect of the invention that is subsequently freeze dried to provide the solid composition of the first aspect of the invention.
- all of the embodiments described in the first aspect of the invention in relation to the aqueous composition apply equally to the reconstituted aqueous composition of the second aspect of the invention.
- the volume of the reconstituted aqueous composition is not necessarily the same as the volume of the aqueous composition in the first aspect of the invention, so the concentrations of components in these compositions may differ from each other.
- the aqueous composition in the first aspect of the invention could have a concentration of a component of 300 mg/mL, but if it is reconstituted in double the volume after lyophilisation, the concentration of that component in the reconstituted aqueous composition would be 150 mg/mL.
- the reconstituting comprises adding an aqueous dispersion medium to the solid composition as defined herein, the aqueous dispersion medium being preferably water.
- the dispersion medium comprises one or more other active agents, in particular one or more other antiretroviral agents, in particular one or more other antiretroviral agents of another class, for example an antiretroviral of the INSTI class, for example cabotegravir.
- the aqueous dispersion medium is an aqueous solution of cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, e.g. CMC or a pharmaceutically acceptable salt thereof.
- the aqueous dispersion medium is an aqueous solution of sodium CMC.
- aqueous composition described herein can be transformed into the solid composition of the invention by freeze drying the aqueous composition using standard procedures known in the art.
- An example procedure is provided below:
- Vials are filled with the aqueous composition. Lyophilisation is performed on a laboratory scale freezedryer (LyoStar3, SP Scientific, USA). Freezing is conducted at -40 °C (shelf inlet temperature) for 60 minutes including equilibrating steps at +5 °C then -5 °C for 15 minutes each. An annealing step at -20°C (shelf inlet temperature) for 90 minutes is implemented.
- the shelf temperature ramp rates from the freezing set-point to the primary drying shelf temperature setting are 1 °C/min throughout the process.
- the shelf inlet temperature set-point during primary drying is about -20°C and secondary drying is about 25 °C.
- the holding time (soak period) of these steps is 600 minutes respectively 60 minutes to allow a modulation in water content in the samples.
- the chamber pressure during primary and secondary drying is about 100 mT orr for primary drying step and about 300 mTorr for the secondary drying step.
- Product temperatures during freeze drying are measured using wired thermocouples. Each thermocouple wire is positioned bottom-centre of the vial to obtain both a representative temperature monitoring in the product and an accurate endpoint detection of the ice sublimation phase.
- the reconstituted aqueous composition can be used to treat or prevent a disease or disorder in a subject, i.e. the reconstituted aqueous composition is for use in therapy.
- the invention relates to a method for the treatment or prevention of a disease or disorder in a subject, the method comprising administering to the subject the reconstituted aqueous composition as defined herein.
- the invention relates to the reconstituted aqueous composition as defined herein for use in the treatment or prevention of a disease or disorder in a subject.
- the invention relates to use of the reconstituted aqueous composition as defined herein for the manufacture of a medicament for treating or preventing a disease or disorder in a subject.
- a solid composition as defined herein for use in the treatment or prevention of a disease or disorder in a subject.
- the use of the solid composition as defined herein for the manufacture of a medicament for treating or preventing a disease or disorder in a subject.
- the subject is a human.
- the drug is present (and is administered to the subject) in a therapeutically effective amount.
- therapeutically effective amount it is meant an amount sufficient to provide a therapeutic effect.
- the disease or disorder is chronic and long-term diseases and disorders, for example chronic viral infection (such as chronic infection with Varicella- zoster virus, measles virus, HIV, hepatitis B virus, hepatitis C virus, hepatitis D virus or human cytomegalovirus), cancer, psychiatric diseases and disorders, mood disorders (such as bipolar, cyclothymic or depression), diabetes, hypertension, abnormal cholesterol and triglyceride levels, inflammatory disorders (such as allergy, asthma, autoimmune diseases, coeliac disease, hepatitis, inflammatory bowel disease, Crohn disease, gout, myositis, scleroderma, rheumatoid arthritis, lupus vasculitis, ankylosing spondylitis or chronic obstructive pulmonary disease), cystic fibrosis, multiple sclerosis, autoimmune disorders, neurodegenerative disorders (such as Parkinson’s Disease or Alzheimer’s disease), chronic pain, inherited metabolic disorders or
- the disease or disorder is HIV infection.
- the HIV is HIV type 1 (HIV-1).
- the drug is preferably rilpivirine or a pharmaceutically acceptable salt thereof, more preferably rilpivirine.
- the reconstituted aqueous composition is administered to the subject intermittently such that the time interval between administrations (i.e. the dosing interval) is about three months to about two years. In an embodiment, the time interval is about three months to about eighteen months. In an embodiment, the time interval is about three months to about one year. In an embodiment, the time interval is about three months to about six months. In an embodiment, the time interval is about six months to about one year. In an embodiment, the time interval is about one year. In an embodiment, the time interval is about three months. In an embodiment, the time interval is about six months.
- the reconstituted aqueous composition is administered to the subject intermittently such that the time interval between administrations (i.e. the dosing interval) is about three months, or of about four months, or of about five months, or of about six months or, of about seven months, or of about eight months, or of about nine months, or of about ten months, or of about eleven months, or of about one year, or of about one year to about two years.
- the reconstituted aqueous composition is administered to the subject intermittently such that the time interval between administrations is as defined in any of the embodiments above and the drug is rilpivirine or a pharmaceutically acceptable salt thereof.
- the reconstituted aqueous composition is administered by subcutaneous injection or intramuscular injection.
- the reconstituted aqueous composition is administered by intramuscular injection.
- the reconstituted aqueous composition is administered by subcutaneous injection.
- the reconstituted aqueous composition is administered by a manual injection process.
- each administration comprises up to about 600 mL of the reconstituted aqueous composition described herein. In another embodiment, each administration comprises from about 3 mL to about 600 mL of the reconstituted aqueous composition. In another embodiment each administration comprises from about 3 mL to about 150mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 3 mL to about 150mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 5 mL to about 150mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 5 mL to about 100 mL of the reconstituted aqueous composition.
- each administration comprises from about 5 mL to about 50 mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 5 mL to about 25 mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 5 mL to about 20 mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 5 mL to about 10 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises up to about 150 mL of the reconstituted aqueous composition described herein. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 3 mL to about 150mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 3 mL to about 100mL of the reconstituted aqueous composition. In another embodiment, each administration comprises from about 3 mL to about 25 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 3 mL to about 15mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 5 mL to about 25 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 6 mL to about 20 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 6 mL to about 18 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 6 mL to about 15 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 6 mL to about 12 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 9 mL to about 18 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 9 mL to about 15 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises from about 9 mL to about 12 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 3 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 6 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 7 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 9 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 12 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 15 mL of the reconstituted aqueous composition. In another embodiment, the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 18 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and each administration comprises about 3 mL, about 7 mL, or about 15 mL of the reconstituted aqueous composition.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and is for the treatment of HIV infection, wherein the dose of rilpivirine or pharmaceutically acceptable salt thereof to be administered may be calculated on a basis of from about 300 mg to about 1200 mg/month, or from about 450 mg to about 1200 mg/month, or from about 450 mg to about 900 mg/month, or from about 600 mg to about 900 mg/month, or from about 450 mg to about 750 mg/month, or about 450 mg/month, or about 600 mg/month, or about 750 mg/month, or about 900 mg/month.
- Doses for other dosing regimens can readily be calculated by multiplying the monthly dose with the number of months between each administration.
- the dose of rilpivirine or pharmaceutically acceptable salt thereof to be administered in each administration is 2700 mg.
- the indicated “mg” corresponds to mg of rilpivirine (i.e. rilpivirine in its free base form).
- 1 mg of rilpivirine (i.e. rilpivirine in its free base form) corresponds to 1 .1 mg of rilpivirine hydrochloride.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and is for the treatment of HIV infection
- the dose of rilpivirine or pharmaceutically acceptable salt thereof to be administered may be calculated on a basis of from about 300 mg to about 1200 mg/4 weeks (28 days), or from about 450 mg to about 1200 mg/4 weeks (28 days), or from about 450 mg to about 900 mg/4 weeks (28 days), or from about 600 mg to about 900 mg/4 weeks (28 days), or from about 450 mg to about 750 mg/4 weeks (28 days) or about 450 mg/4 weeks (28 days), or about 600 mg/4 weeks (28 days), or about 750 mg/4 weeks (28 days) or about 900 mg/4 weeks (28 days).
- Doses for other dosing regimens can readily be calculated by multiplying the week or day dose with the number of weeks between each administration. For example, in case of a dose of 450 mg/4 weeks (28 days), and in case of a time interval of 24 weeks between each administration, the dose of rilpivirine or pharmaceutically acceptable salt thereof to be administered in each administration is 2700 mg. Or for example, in case of a dose of 750 mg/4 weeks (28 days), and in case of a time interval of 24 weeks between each administration, the dose of rilpivirine or pharmaceutically acceptable salt thereof to be administered in each administration is 4500 mg.
- the indicated “mg” corresponds to mg of rilpivirine (i.e. rilpivirine in its free base form).
- 1 mg of rilpivirine i.e. rilpivirine in its free base form
- the drug is rilpivirine or pharmaceutically acceptable salt thereof
- the rilpivirine or pharmaceutically acceptable salt thereof in the reconstituted aqueous composition is used in an amount such that the blood plasma concentration of rilpivirine in the subject is kept at a level above about 12 ng/ml, preferably ranging from about 12 ng/ml to about 100 ng/ml, more preferably from about 12 ng/ml to about 50 ng/ml for at least
- the rilpivirine or pharmaceutically acceptable salt thereof in the reconstituted aqueous composition is used in an amount such that the blood plasma concentration of rilpivirine in the subject is kept at a level of from about 12 ng/ml to about 100 ng/ml for at least 6 months.
- the drug is rilpivirine or pharmaceutically acceptable salt thereof and is for the prevention of HIV infection, wherein each administration of rilpivirine or pharmaceutically acceptable salt thereof may comprise the same dosing as for therapeutic applications as described above.
- the reconstituted aqueous composition comprises a drug as defined herein and is used in combination with one or more other drugs, in particular one or more other antiretroviral agents, in particular one or more other antiretroviral agents of another class, such as for example an antiretroviral of the INSTI class, such as for example cabotegravir.
- said one or more other antiretroviral agents e.g. cabotegravir
- said one or more other antiretroviral agents is administered as an intramuscular or subcutaneous injection, in particular as an injectable micro- or nanosuspension, at a time interval of about three months to about two years.
- said one or more other antiretroviral agent e.g. cabotegravir
- the reconstituted aqueous composition and the other antiretroviral agent are administered intermittently at a time interval of about three months, or of about four months, or of about five months or of about six months or of about seven months or of about eight months or of about ten months or of about eleven months or of about one year or of about one year to about 2 years.
- the reconstituted aqueous composition and the one or more other antiretroviral agents e.g. cabotegravir
- the reconstituted aqueous composition and the one or more other antiretroviral agents, e.g. cabotegravir are administered simultaneously, in particular by subcutaneous injection.
- the reconstituted aqueous composition and the one or more other antiretroviral agents are administered sequentially, in particular by subcutaneous injection.
- the reconstituted aqueous composition is administered first followed by a cabotegravir injection.
- treatment of HIV infection relates to the treatment of a subject infected with HIV.
- treatment of HIV infection also relates to the treatment of diseases associated with HIV infection, for example AIDS, or other conditions associated with HIV infection including thrombocytopaenia, Kaposi's sarcoma and infection of the central nervous system characterized by progressive demyelination, resulting in dementia and symptoms such as, progressive dysarthria, ataxia and disorientation, and further conditions where HIV infection has also been associated with, such as peripheral neuropathy, progressive generalized lymphadenopathy (PGL), and AIDS-related complex (ARC).
- PDL progressive generalized lymphadenopathy
- ARC AIDS-related complex
- prevention of HIV infection relates to the prevention or avoidance of a subject (who is not infected with HIV) becoming infected with HIV.
- the source of infection can be various, a material containing HIV, in particular a body fluid that contains HIV such as blood or semen, or another subject who is infected with HIV.
- Prevention of HIV infection relates to the prevention of the transmission of the virus from the material containing HIV or from the HIV infected individual to an uninfected person, or relates to the prevention of the virus from entering the body of an uninfected person.
- Transmission of the HIV virus can be by any known cause of HIV transfer such as by sexual transmission or by contact with blood of an infected subject, e.g. medical staff providing care to infected subjects. Transfer of HIV can also occur by contact with HIV infected blood, e.g. when handling blood samples or with blood transfusion. It can also be by contact with infected cells, e.g. when carrying out laboratory experiments with HIV infected cells.
- treatment of HIV infection refers to a treatment by which the viral load of HIV (represented as the number of copies of viral RNA in a specified volume of serum) is reduced.
- the viral load should be reduced to as low levels as possible, e.g. below about 200 copies/mL, in particular below about 100 copies/mL, more in particular below 50 copies/mL, if possible below the detection limit of the virus.
- Reductions of viral load of one, two or even three orders of magnitude are an indication of the effectiveness of the treatment.
- CD4 count Another parameter to measure effectiveness of HIV treatment is the CD4 count, which in normal adults ranges from 500 to 1500 cells per pL. Lowered CD4 counts are an indication of HIV infection and once below about 200 cells per pL, AIDS may develop. An increase of CD4 count, e.g. with about 50, 100, 200 or more cells per pL, is also an indication of the effectiveness of anti-HIV treatment. The CD4 count in particular should be increased to a level above about 200 cells per pL, or above about 350 cells per pL. Viral load or CD4 count, or both, can be used to diagnose the degree of HIV infection. Another parameter to measure effectiveness of HIV treatment is keeping the HIV infected subject virologically suppressed (HIV-1 RNA ⁇ 50 copies/mL) when on the treatment according to the present invention.
- treatment of HIV infection refers to that treatment that lowers the viral load, or increases CD4 count, or both, or keeps the HIV infected subject virologically suppressed, as described above.
- prevention of HIV infection refers to that situation where there is a decrease in the relative number of newly infected subjects in a population in contact with a source of HIV infection such as a material containing HIV, or a HIV infected subject. Effective prevention can be measured, for example, by measuring in a mixed population of HIV infected and non- infected individuals, if there is a decrease of the relative number of newly infected individuals, when comparing non- infected individuals treated with a pharmaceutical composition of the invention, and non-treated non-infected individuals. This decrease can be measured by statistical analysis of the numbers of infected and non-infected individuals in a given population over time.
- cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof for stabilising a hyaluronidase in a solid composition, in particular a freeze dried composition, comprising a drug.
- a ninth aspect there is provided a method for stabilising a hyaluronidase in a solid composition comprising a drug, the method comprising freeze drying an aqueous composition comprising the hyaluronidase, the drug and cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof in the eighth or ninth aspects of the invention may be any one of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof defined in relation to the first aspect of the invention.
- the solid composition in the eighth or ninth aspects of the invention may be any one of the solid compositions as defined in relation to the first aspect of the invention.
- the hyaluronidase in the eighth or ninth aspects of the invention may be any one of the hyaluronidases as defined in relation to the first aspect of the invention.
- the drug in the eighth or ninth aspects of the invention may be any one of the drugs as defined in relation to the first aspect of the invention.
- kits comprising: (i) the solid composition of the invention as described herein, and (ii) a diluent, in particular a diluent to reconstitute the solid composition (i).
- kits comprising: (i) the solid composition of the invention as described herein, and (ii) a composition comprising one or more other drugs, in particular one or more other antiretroviral agents, in particular one or more other antiretroviral agents of another class, such as for example an antiretroviral of the INSTI class, such as for example cabotegravir, and optionally (iii) a diluent, in particular a diluent to reconstitute the solid composition (i).
- a composition comprising one or more other drugs, in particular one or more other antiretroviral agents, in particular one or more other antiretroviral agents of another class, such as for example an antiretroviral of the INSTI class, such as for example cabotegravir, and optionally (iii) a diluent, in particular a diluent to reconstitute the solid composition (i).
- composition “comprising” encompasses “including” as well as “consisting”, e.g. a composition “comprising” X may consist exclusively of X or may include something additional, e.g. X + Y.
- composition “comprising” used herein also encompasses “consisting essentially of’, e.g. a composition “comprising” X may consist of X and any other components that do not materially affect the essential characteristics of the composition.
- Y is optional and means, for example, Y ⁇ 10%.
- a time interval When a time interval is expressed as a specified number of months, it runs from a given numbered day of a given month to the same numbered day of the month that falls the specified number of months later. Where the same numbered day does not exist in the month that falls the specified number of months later, the time interval runs into the following month for the same number of days it would have run if the same numbered day would exist in the month that falls the specified number of months later.
- a time interval When a time interval is expressed as a number of years, it runs from a given date of a given year to the same date in the year that falls the specified number of years later. Where the same date does not exist in the year that falls the specified number of years later, the time interval runs for the same number of days it would have run if the same numbered day would exist in the month that falls the specified number of months later. In other words, if the time interval starts on 29th February of a given year but ends in a year where there is no 29th February, the time period ends instead on 1st March in that year.
- the term “about” in relation to such a definition means that the time interval may end on a date that is ⁇ 10% of the time interval.
- the time interval may start up to 7 days before or after the start of the time interval and end up to 7 days before or after the end of the time interval.
- This example compares the T m of a hyaluronidase in various compositions, each having a different combination of excipients and/or pH.
- a higher T m indicates higher thermal stability.
- a T m of from about 25 to about 30 °C higher than the intended long term storage conditions targeted to provide optimal thermodynamic stability of the hyaluronidase.
- composition A comprising the following excipients was prepared:
- compositions 1-5 were prepared by adding the component(s) shown in Table 1 below to the composition A, and adjusting the pH to 6.0, 6.5, or 7.0 as necessary by varying the amount of the sodium hydroxide in the composition.
- compositions 1-5 were prepared as set out above and then stored in a refrigerator at 5 °C for between 2 days and 2 weeks.
- the T m for the hyaluronidase was then measured for each of the compositions straight away.
- the T m was calculated using nano differential scanning fluorimetry (nDSF) assays.
- nDSF uses the intrinsic tryptophan and tyrosine fluorescence to monitor hyaluronidase unfolding.
- the T m values in this example were measured using nDSF assays as follows.
- a Prometheus NT.Plex instrument controlled by PR.ThermControl-CFR software was used to run all nDSF assays.
- a temperature range of 20-95 °C with a temperature gradient of 1 °C/min was used when measuring the samples.
- An excitation power of 95% was used in all cases.
- the instrument determined the fluorescence ratio of 350 nm (tryptophan) and 330 nm (tyrosine) of the hyaluronidase during a heat ramp to 95 °C.
- the unfolding onset temperature (T on ) and the inflection points (T m ) of the present unfolding transitions were then calculated from the unfolding curve.
- the nanoDSF instrument was operated in combination with a robotic autosampler.
- the autosampler performs loading and transfer of the capillary chips from a 384-well plate for nanoDSF measurements.
- the preparation of the 384-well plate was automated using a Tecan Fluent 760 liquid handling system in combination with custom-made sample holders for 2R vials that were typically provided for sample testing.
- Example 1b - Hyaluronidase melting temperature under different storage conditions This example compares the fluorescence emission spectra of rHuPH20 compositions after storage under different conditions. Fluorescence emission spectroscopy uses a beam of light which is absorbed by a hyaluronidase, causing a fluorophore in the ground state to be excited to a higher energy state, thereby resulting in emission. For a hyaluronidase such as rHuPH20, the fluorescence of tryptophan may be used to measure a change in tertiary hyaluronidase structure during or after storage under different conditions, and thus quantify the thermal stability of the hyaluronidase. The maximum emission wavelengths for folded and unfolded rHuPH20 are 330 nm and 350 nm, respectively.
- compositions 6-10 were prepared by adding the component(s) shown in Table 2 below to composition A of Example 1a, and adjusting the pH to 6.0, 6.5, or 7.0 as necessary by varying the amount of the sodium hydroxide in the composition.
- composition preparation The spectra of the compositions were collected immediately after storage at 5 °C and after storage at 40 °C for one and two weeks. In addition to peak maximum and minimum, the intensity ratio 350/330 nm was calculated and plotted as a function of storage time. The slope of this curve was used to have a semi-quantitative assessment and comparison among compositions.
- the fluorescence emission spectrum of the samples was measured before and after stressing via a Tecan plate reader (Infinite 200). The following method parameters were used:
- This example compares the T m of a hyaluronidase in various compositions under different storage conditions.
- composition B comprising the following excipients was prepared:
- compositions 11-14 were then prepared by adding the component(s) as shown in Table 3 to the composition B, and the pH was adjusted to 6.0 by varying the amount of sodium hydroxide in the composition.
- in the T m columns means that the hyaluronidase was denatured due to the applied temperature stress.
- Table 3 T m under different storage conditions Compositions 11-14 were prepared as set out above and then stored in a refrigerator at
- the pH of the compositions was remeasured immediately before the T m values were measured.
- the remeasured pH was 5.93, 5.96, and 5.92 for compositions 11 , 12, and 13, respectively.
- This example examines the dependence of T m on sodium CMC concentration.
- composition C comprising the following excipients was prepared:
- compositions 15-20 were then prepared by adding sodium CMC shown in Table 4 below to the above composition C, and the pH was adjusted to 6.0 by varying the amount of sodium hydroxide in the composition.
- Table 4 Sodium CMC concentration Compositions 15-20 were prepared as set out above and then stored in a refrigerator at 5 °C between 2 days and 2 weeks. T m values were then measured using the method described in Example 1a.
- aqueous compositions according to the invention comprising drug nanoparticles in suspension were freeze dried to explore the effect of this process on the particle size of the drug in the corresponding reconstituted aqueous compositions.
- Aqueous compositions of a drug (rilpivirine) in the form of nanoparticles (having Dv10 of about 96.5 nm, Dv50 of about 224 nm, and Dv90 of about 509 nm) with the following excipients were prepared:
- the drug particle sizes were measured in all instances following the method below.
- the volume-based particle size distribution of the drug suspensions was determined by means of wet dispersion laser diffraction, using a Malvern Mastersizer 3000 laser diffraction (Malvern Instruments) and Hydro MV wet dispersion module.
- This example explores the effect that freeze drying aqueous compositions comprising a hyaluronidas and rilpivirine has on hyaluronidase stability in the corresponding reconstituted aqueous compositions.
- Hyaluroidase stability was evaluated through one or more of the following: (i) activity (bioassay method); (ii) quantification/aggregation (size-exclusion chromatography/SEC); and (iii) purity (reversed-phase liquid chromatography/RP-LC).
- SEC is a size exclusion chromatographic separation method whereby a column is used to distribute the molecules within the solution flowing through according to their broad size range. Monomers, aggregates and fragments elute at different times from the column and hence their relative proportions in a sample can be quantified using a standard UV detector. The results are shown in Table 7.
- 0x1 and 0x2 are oxidised forms of rHuPH20. 0x1 retains more enzymatic activity than 0x2. 0x1 and 0x2 are less active than rHuPH20.
- Example 7 Freeze drying, hyaluronidase stability, and rilpivirine particle size studies under different storage conditions
- This example explores the effect that freeze drying aqueous compositions comprising a hyaluronidase and rilpivirine has on collapse temperature, hyaluronidase stability, viscosity and injection force in the corresponding reconstituted aqueous compositions.
- compositions were freeze dried and the collapse temperature was determined. The results are shown in Table 9.
- compositions and T c The freeze dried compositions all had a relatively low water content ( ⁇ 1% as determined by Karl Fisher). The appearance of all compositions was acceptable. The compositions were then reconstituted with water to provide 9 mL of the reconstituted aqueous composition after being stored under the following conditions:
- Hyaluronidase stability was evaluated through one or more of the following: (i) activity (bioassay method); (ii) quantification/aggregation (size-exclusion chromatography/SEC) and (iii) purity (reversed-phase liquid chromatography/RP-LC).
- the rilpivirine particle sizes were measured as follows.
- the volume-based particle size distribution of the rilpivirine suspensions was determined by means of wet dispersion laser diffraction, using a Malvern Mastersizer 3000 laser diffraction (Malvern Instruments) and Hydro MV wet dispersion module.
- the viscosity of the compositions was measured using a HAAKE Mars 60 rheometer.
- the injection force was measured using a 20 mL Luer Lock syringe equipped with 23 G x % inch winged infusion set.
- This example compares the fluorescence emission spectra of rHuPH20 compositions after storage under different conditions.
- the spectra of the compositions were collected immediately after storage at 5 °C and after storage at 50 °C for one day.
- the intensity ratio 350/330 nm was calculated at each time point and plotted as a function of storage time. The slope of this curve was used to have a semi-quantitative thermal stability assessment and comparison among compositions.
- the fluorescence emission spectrum of the samples was measured before and after stressing via a Tecan plate reader (Infinite 200). The following method parameters were used:
- Table 10 Slope of the ratio between 350 nm / 330 nm versus time Example 9 - Melting temperature studies under different storage conditions
- This example compares the melting temperatures of rHuPH20 in various compositions under different storage conditions.
- compositions of rilpivirine nanoparticles having Dv10 of 75-200 nm, Dv50 of 200-500 nm, and Dv90 of 500-1600 nm) with the following excipients were prepared:
- compositions 39-124 were then prepared by adding the component(s) as shown in Table 11 , and the pH was adjusted to 6.0 by varying the amount of sodium hydroxide in the composition.
- N/A* Note that for high sodium CMC concentrations (>17 mg/mL) the capillary chips of the nanoDSF instrument could not be loaded, presumably due to high solution viscosity.
- N/A** Note that for these conditions either the hyaluronidase was denatured due to the applied temperature stress, or the capillaries could not be loaded to high viscosity Table 11 : T m under different storage conditions
- compositions 39-124 were prepared as set out above and then stored in a refrigerator at
- T m 5 °C between 2 days and 2 weeks.
- a solid composition obtainable by freeze drying an aqueous composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug.
- aqueous composition comprises from about 1 ,500 U/mL to about 2,500 U/mL hyaluronidase.
- aqueous composition comprises from about 1 ,800 U/mL to about 2,200 U/mL hyaluronidase.
- aqueous composition comprises about 2,000 U/mL hyaluronidase.
- aqueous composition comprises from about 1 to about 100 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- aqueous composition comprises from about 1 to about 50 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- aqueous composition comprises from about 10 to about 25 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof.
- aqueous composition comprises from about 1 to about 5 mg/mL of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, for example about 3 mg/mL.
- aqueous composition comprises from about 0.01 mg to about 5 mg of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- aqueous composition comprises from about 0.05 mg to about 2.5 mg of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition comprises from about 0.05 mg to about 0.25 mg of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase, for example about 0.15 mg of the cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- the aqueous composition additionally comprises a cryoprotectant.
- aqueous composition comprises from about 75 mg/mL to about 125 mg/mL of the cryoprotectant, for example about 100 mg/mL of the cryoprotectant.
- the aqueous composition comprises from about 25 mg/mL to about 35 mg/mL of the cryoprotectant, for example about 30 mg/mL of the cryoprotectant.
- the drug is selected from: drugs for treatment of chronic and long-term diseases and disorders, for example for treatment of chronic viral infection (such as chronic infection with varicellazoster virus, measles virus, HIV, hepatitis B virus, hepatitis C virus, hepatitis D virus or human cytomegalovirus), cancer, psychiatric diseases and disorders, mood disorders (such as bipolar, cyclothymic or depression), diabetes, hypertension, abnormal cholesterol and triglyceride levels, inflammatory disorders (such as allergy, asthma, autoimmune diseases, coeliac disease, hepatitis, inflammatory bowel disease, Crohn disease, gout, myositis, scleroderma, rheumatoid arthritis, lupus vasculitis, ankylosing spondylitis or chronic obstructive pulmonary disease), cystic fibrosis, multiple sclerosis, autoimmune disorders, neurodegenerative disorders (such as chronic viral infection with varicellazoster virus, measles virus, HIV
- aqueous composition additionally comprises a surface modifying agent, a buffering agent and/or a pH adjusting agent, and/or a chelating agent.
- aqueous composition additionally comprises one or more of a poloxamer, sodium dihydrogen phosphate, citric acid and sodium hydroxide, optionally wherein the aqueous composition additionally comprises a poloxamer, sodium dihydrogen phosphate, citric acid and sodium hydroxide.
- aqueous composition additionally comprises a poloxamer, for example poloxamer 338.
- aqueous composition additionally comprises poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate and sodium hydroxide.
- aqueous composition additionally comprises an antioxidant, optionally wherein the antioxidant is methionine.
- aqueous composition comprises from about 1 .0 mg/mL to about 2.0 mg/mL of the antioxidant, for example about 1.5 mg/mL.
- a method for stabilising a hyaluronidase in a solid composition comprising freeze drying an aqueous composition comprising the hyaluronidase and cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and a drug.
- a method for stabilising a hyaluronidase in a solid composition comprising freeze drying an aqueous composition comprising the hyaluronidase and cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and a drug.
- a solid composition obtainable by freeze drying an aqueous composition comprising (i) a hyaluronidase, (ii) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof, and (iii) a drug.
- aqueous composition comprises from about 0.01 mg to about 5 mg cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof per 100 U hyaluronidase.
- cryoprotectant is a sugar, optionally wherein the sugar is mannitol or sucrose.
- the solid composition according to any one of the preceding embodiments wherein the aqueous composition has a pH of about 6-7, optionally about 6. 11 .
- the solid composition according to any one of the preceding embodiments wherein the drug is rilpivirine and the rilpivirine is in the form of particles suspended in the aqueous composition, optionally wherein the particles are micro- or nanoparticles suspended in the aqueous composition.
- a reconstituted aqueous composition obtainable by reconstituting the solid composition as defined in any one of embodiments 1-11 with an aqueous dispersion medium.
- a method for the treatment or prevention of a disease or disorder in a subject comprising administering to the subject a reconstituted aqueous composition as defined in embodiment 12.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333557P | 2022-04-22 | 2022-04-22 | |
| US63/333,557 | 2022-04-22 | ||
| EP22173920.4 | 2022-05-17 | ||
| EP22173920 | 2022-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023203257A1 true WO2023203257A1 (en) | 2023-10-26 |
Family
ID=86330122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/060688 Ceased WO2023203257A1 (en) | 2022-04-22 | 2023-04-24 | Freeze dried compositions |
| PCT/EP2023/060686 Ceased WO2023203255A1 (en) | 2022-04-22 | 2023-04-24 | Freeze dried compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/060686 Ceased WO2023203255A1 (en) | 2022-04-22 | 2023-04-24 | Freeze dried compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250275967A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511007A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513501A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403545A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249784A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW202406551A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023203257A1 (cg-RX-API-DMAC7.html) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078140A2 (en) | 2003-03-05 | 2004-09-16 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| WO2008110619A1 (en) * | 2007-03-14 | 2008-09-18 | Tibotec Pharmaceuticals Ltd. | Powders for reconstitution |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| EP3799860A1 (en) * | 2011-04-15 | 2021-04-07 | Janssen Pharmaceutica NV | Freeze dried drug nanosuspensions |
| WO2022109555A1 (en) * | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
| GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
-
2023
- 2023-04-24 WO PCT/EP2023/060688 patent/WO2023203257A1/en not_active Ceased
- 2023-04-24 JP JP2024562210A patent/JP2025513501A/ja active Pending
- 2023-04-24 TW TW112115224A patent/TW202406551A/zh unknown
- 2023-04-24 TW TW112115222A patent/TW202408580A/zh unknown
- 2023-04-24 EP EP23722287.2A patent/EP4511007A1/en active Pending
- 2023-04-24 CA CA3249784A patent/CA3249784A1/en active Pending
- 2023-04-24 US US18/858,037 patent/US20250275967A1/en active Pending
- 2023-04-24 CN CN202380048657.2A patent/CN119403545A/zh active Pending
- 2023-04-24 WO PCT/EP2023/060686 patent/WO2023203255A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078140A2 (en) | 2003-03-05 | 2004-09-16 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| WO2008110619A1 (en) * | 2007-03-14 | 2008-09-18 | Tibotec Pharmaceuticals Ltd. | Powders for reconstitution |
| EP3799860A1 (en) * | 2011-04-15 | 2021-04-07 | Janssen Pharmaceutica NV | Freeze dried drug nanosuspensions |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| WO2022109555A1 (en) * | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
Non-Patent Citations (3)
| Title |
|---|
| CAS , no. 757971-58-7 |
| IZUTSU KEN-ICHI: "Physical stability and protein stability of freeze-dried cakes during storage at elevated temperatures", 7 February 1994 (1994-02-07), XP055978663, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1023/A:1018931319772.pdf> [retrieved on 20221107] * |
| JAMES J. HOBSON ET AL: "Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies", NATURE COMMUNICATIONS, vol. 10, no. 1, 29 March 2019 (2019-03-29), XP055683254, DOI: 10.1038/s41467-019-09354-z * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511007A1 (en) | 2025-02-26 |
| JP2025513501A (ja) | 2025-04-24 |
| WO2023203255A1 (en) | 2023-10-26 |
| CN119403545A (zh) | 2025-02-07 |
| US20250275967A1 (en) | 2025-09-04 |
| TW202408580A (zh) | 2024-03-01 |
| CA3249784A1 (en) | 2023-10-26 |
| TW202406551A (zh) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4211965B2 (ja) | サブミクロンの9−ヒドロキシリスペリドン脂肪酸エステルの水性懸濁液 | |
| JP5249748B2 (ja) | 無菌3−[2−[4−(6−フルオロ−1,2−ベンズイソオキサゾール−3−イル)−1−ピペリジニル]エチル]−6,7,8,9−テトラヒドロ−9−ヒドロキシ−2−メチル−4H−ピリド[1,2−a]ピリミジン−4−オンパルミチン酸エステルの製造 | |
| KR20080105114A (ko) | 나노입자형 카르베디롤 제제 | |
| WO2022008644A1 (en) | Long-acting formulations | |
| KR20210044245A (ko) | 주사가능 약학 조성물 및 이의 제조 방법 | |
| KR20230137312A (ko) | 다이페닐피라진 유도체를 포함하는 약제학적 조성물 | |
| CN114224851A (zh) | 一种人白细胞介素10-Fc融合蛋白的冻干粉制剂及制备方法 | |
| EP4511007A1 (en) | Freeze dried compositions | |
| US20250268896A1 (en) | Liquid compositions | |
| WO2022109555A1 (en) | Treatment or prevention of hiv infection | |
| JP2023549837A (ja) | 疾患又は障害の治療又は予防 | |
| WO2024068693A1 (en) | Long-acting formulations | |
| EP4593834A1 (en) | Long-acting formulations | |
| JP7837861B2 (ja) | 薬物組成物 | |
| TW202333725A (zh) | 溶出測試 | |
| CN117224492A (zh) | 阿可拉定纳米晶及其制备方法 | |
| HK40113410A (en) | Dissolution test | |
| CN118251210A (zh) | 溶出测试 | |
| WO2023214059A1 (en) | Diphenylpyrazine compounds as prodrugs | |
| CN111249239A (zh) | 一种氯雷他定纳米晶体及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23722288 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 23722288 Country of ref document: EP Kind code of ref document: A1 |